More News! Needle-Free Vaccines, Spinal Cord Implants and Gene Therapy Action

Try as we might, we can’t cover all the biotech news out there! Here’s a roundup of news that didn’t make the cut over the last week.

More Biotech News -MEDICALheader

  • Enesi Pharma, an Oxford-based biotech developing novel needle-free vaccines, is partnering with Public Health England to develop vaccines for emergent threat pathogens
  • German Bayer spin-off AiCuris will collaborate with Canadian biotech Cyclenium Pharma to use their combined expertise in infectious diseases to develop new treatments for bacterial and viral infections
  • French CAR-Treg autoimmune-disease biotech TxCell has completed the final details of its acquisition deal and become a subsidiary of US-based Sangamo Therapeutics, which plans to develop the technology further
  • French company Novasep has opened €27M facility in Seneffe, Belgium to produce viral vectors for use in gene therapies, a rapidly growing field
  • The opium poppy genome has been assembled thanks to a Chinese, English and Israeli collaboration, which the researchers hope will lead to the development of more affordable and reliable medicines
  • Swedish company BioArctic has been granted a European patent for an implant that is designed to treat complete spinal cord injury
  • A branch of UK-based Premaitha Health, a molecular diagnostics company, will partner with an unspecified clinical research organisation in Taiwan to provide next generation sequencing services for oncology patients
  • US-based IQVIA and Genomics England will develop a research platform for scientists combining clinical and genomic data to help advance the development of personalized medicines
  • US-biotech bluebird bio’s LentiGlobin one-time gene therapy for treatment of transfusion-dependent β-thalassemia has had its marketing authorisation application accepted in Europe
  • London-based venture capital firm Arix Bioscience invested €50M in series A funding for US-biotech VelosBio, which is developing antibody-drug conjugates for treating blood cancer and solid tumors

More Biotech News - INDUSTRIAL subhead


  • Cambridge-based synthetic biology company Evonetix aims to scale up its DNA synthesis technology by partnering with Dutch customised microsystem company LioniX International
  • SynbiCITE, the national centre for commercialization of synthetic biology in the UK, announced the launch of a new 5-year strategy that will be funded by a €5.7M grant from UK Research and Innovation, as well as other investors

Images: E. Resko & Shutterstock

Support good journalism, subscribe to Labiotech Insider

Labiotech Insider

If you liked this post and want to read more good journalism, support us by joining Labiotech Insider. Our Insider membership gives you access to exclusive content and other advantages.

We use cookies to give you the best experience. If you click on accept, we also use tracking cookies for analytics and advertising purposes. Check our privacy policy for more details. By accepting, you support our independent media and its’ freely accessible content. You may withdraw your consent at any time.